Connection
David Lynch to Iron-Binding Proteins
This is a "connection" page, showing publications David Lynch has written about Iron-Binding Proteins.
|
|
Connection Strength |
|
 |
|
 |
|
4.688 |
|
|
|
-
Isaacs CJ, Brigatti KW, Kucheruk O, Ratcliffe S, Sciascia T, McCormack SE, Willi SM, Lynch DR. Effects of genetic severity on glucose homeostasis in Friedreich ataxia. Muscle Nerve. 2016 11; 54(5):887-894.
Score: 0.535
-
Deutsch EC, Oglesbee D, Greeley NR, Lynch DR. Usefulness of frataxin immunoassays for the diagnosis of Friedreich ataxia. J Neurol Neurosurg Psychiatry. 2014 Sep; 85(9):994-1002.
Score: 0.446
-
Lynch DR, Deutsch EC, Wilson RB, Tennekoon G. Unanswered questions in Friedreich ataxia. J Child Neurol. 2012 Sep; 27(9):1223-9.
Score: 0.402
-
Deutsch EC, Santani AB, Perlman SL, Farmer JM, Stolle CA, Marusich MF, Lynch DR. A rapid, noninvasive immunoassay for frataxin: utility in assessment of Friedreich ataxia. Mol Genet Metab. 2010 Oct-Nov; 101(2-3):238-45.
Score: 0.349
-
Stolle CA, Frackelton EC, McCallum J, Farmer JM, Tsou A, Wilson RB, Lynch DR. Novel, complex interruptions of the GAA repeat in small, expanded alleles of two affected siblings with late-onset Friedreich ataxia. Mov Disord. 2008 Jul 15; 23(9):1303-6.
Score: 0.304
-
Lynch DR, Rojsajjakul T, Subramony SH, Perlman SL, Keita M, Mesaros C, Blair IA. Frataxin analysis using triple quadrupole mass spectrometry: application to a large heterogeneous clinical cohort. J Neurol. 2024 Apr; 271(4):1844-1849.
Score: 0.221
-
Rodden LN, Rummey C, Kessler S, Wilson RB, Lynch DR. A Novel Metric for Predicting Severity of Disease Features in Friedreich's Ataxia. Mov Disord. 2023 06; 38(6):970-977.
Score: 0.210
-
Li Y, Li J, Wang J, Lynch DR, Shen X, Corey DR, Parekh D, Bhat B, Woo C, Cherry JJ, Napierala JS, Napierala M. Targeting 3' and 5' untranslated regions with antisense oligonucleotides to stabilize frataxin mRNA and increase protein expression. Nucleic Acids Res. 2021 11 18; 49(20):11560-11574.
Score: 0.192
-
Weng L, Laboureur L, Wang Q, Guo L, Xu P, Gottlieb L, Lynch DR, Mesaros C, Blair IA. Extra-mitochondrial mouse frataxin and its implications for mouse models of Friedreich's ataxia. Sci Rep. 2020 09 25; 10(1):15788.
Score: 0.177
-
Weng L, Wang Q, Yu S, Yang X, Lynch DR, Mesaros C, Blair IA. Evaluation of antibodies for western blot analysis of frataxin protein isoforms. J Immunol Methods. 2019 11; 474:112629.
Score: 0.163
-
Lynch DR, Hauser L, McCormick A, Wells M, Dong YN, McCormack S, Schadt K, Perlman S, Subramony SH, Mathews KD, Brocht A, Ball J, Perdok R, Grahn A, Vescio T, Sherman JW, Farmer JM. Randomized, double-blind, placebo-controlled study of interferon-? 1b in Friedreich Ataxia. Ann Clin Transl Neurol. 2019 03; 6(3):546-553.
Score: 0.159
-
Guo L, Wang Q, Weng L, Hauser LA, Strawser CJ, Mesaros C, Lynch DR, Blair IA. Characterization of a new N-terminally acetylated extra-mitochondrial isoform of frataxin in human erythrocytes. Sci Rep. 2018 11 19; 8(1):17043.
Score: 0.156
-
Wang Q, Guo L, Strawser CJ, Hauser LA, Hwang WT, Snyder NW, Lynch DR, Mesaros C, Blair IA. Low apolipoprotein A-I levels in Friedreich's ataxia and in frataxin-deficient cells: Implications for therapy. PLoS One. 2018; 13(2):e0192779.
Score: 0.148
-
Guo L, Wang Q, Weng L, Hauser LA, Strawser CJ, Rocha AG, Dancis A, Mesaros C, Lynch DR, Blair IA. Liquid Chromatography-High Resolution Mass Spectrometry Analysis of Platelet Frataxin as a Protein Biomarker for the Rare Disease Friedreich's Ataxia. Anal Chem. 2018 02 06; 90(3):2216-2223.
Score: 0.147
-
Li Y, Polak U, Clark AD, Bhalla AD, Chen YY, Li J, Farmer J, Seyer L, Lynch D, Butler JS, Napierala M. Establishment and Maintenance of Primary Fibroblast Repositories for Rare Diseases-Friedreich's Ataxia Example. Biopreserv Biobank. 2016 Aug; 14(4):324-9.
Score: 0.130
-
Galea CA, Huq A, Lockhart PJ, Tai G, Corben LA, Yiu EM, Gurrin LC, Lynch DR, Gelbard S, Durr A, Pousset F, Parkinson M, Labrum R, Giunti P, Perlman SL, Delatycki MB, Evans-Galea MV. Compound heterozygous FXN mutations and clinical outcome in friedreich ataxia. Ann Neurol. 2016 Mar; 79(3):485-95.
Score: 0.129
-
Greeley NR, Regner S, Willi S, Lynch DR. Cross-sectional analysis of glucose metabolism in Friedreich ataxia. J Neurol Sci. 2014 Jul 15; 342(1-2):29-35.
Score: 0.114
-
Deutsch EC, Seyer LA, Perlman SL, Yu J, Lynch DR. Clinical monitoring in a patient with Friedreich ataxia and osteogenic sarcoma. J Child Neurol. 2012 Sep; 27(9):1159-63.
Score: 0.100
-
Regner SR, Wilcox NS, Friedman LS, Seyer LA, Schadt KA, Brigatti KW, Perlman S, Delatycki M, Wilmot GR, Gomez CM, Bushara KO, Mathews KD, Subramony SH, Ashizawa T, Ravina B, Brocht A, Farmer JM, Lynch DR. Friedreich ataxia clinical outcome measures: natural history evaluation in 410 participants. J Child Neurol. 2012 Sep; 27(9):1152-8.
Score: 0.100
-
Evans-Galea MV, Carrodus N, Rowley SM, Corben LA, Tai G, Saffery R, Galati JC, Wong NC, Craig JM, Lynch DR, Regner SR, Brocht AF, Perlman SL, Bushara KO, Gomez CM, Wilmot GR, Li L, Varley E, Delatycki MB, Sarsero JP. FXN methylation predicts expression and clinical outcome in Friedreich ataxia. Ann Neurol. 2012 Apr; 71(4):487-97.
Score: 0.098
-
Selak MA, Lyver E, Micklow E, Deutsch EC, Onder O, Selamoglu N, Yager C, Knight S, Carroll M, Daldal F, Dancis A, Lynch DR, Sarry JE. Blood cells from Friedreich ataxia patients harbor frataxin deficiency without a loss of mitochondrial function. Mitochondrion. 2011 Mar; 11(2):342-50.
Score: 0.090
-
Friedman LS, Farmer JM, Perlman S, Wilmot G, Gomez CM, Bushara KO, Mathews KD, Subramony SH, Ashizawa T, Balcer LJ, Wilson RB, Lynch DR. Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design. Mov Disord. 2010 Mar 15; 25(4):426-32.
Score: 0.085
-
Napierala JS, Rajapakshe K, Clark A, Chen YY, Huang S, Mesaros C, Xu P, Blair IA, Hauser LA, Farmer J, Lynch DR, Edwards DP, Coarfa C, Napierala M. Reverse Phase Protein Array Reveals Correlation of Retinoic Acid Metabolism With Cardiomyopathy in Friedreich's Ataxia. Mol Cell Proteomics. 2021; 20:100094.
Score: 0.046
-
Marty B, Naeije G, Bourguignon M, Wens V, Jousm?ki V, Lynch DR, Gaetz W, Goldman S, Hari R, Pandolfo M, De Ti?ge X. Evidence for genetically determined degeneration of proprioceptive tracts in Friedreich ataxia. Neurology. 2019 07 09; 93(2):e116-e124.
Score: 0.041
-
Long A, Napierala JS, Polak U, Hauser L, Koeppen AH, Lynch DR, Napierala M. Somatic instability of the expanded GAA repeats in Friedreich's ataxia. PLoS One. 2017; 12(12):e0189990.
Score: 0.037
-
Li Y, Lu Y, Polak U, Lin K, Shen J, Farmer J, Seyer L, Bhalla AD, Rozwadowska N, Lynch DR, Butler JS, Napierala M. Expanded GAA repeats impede transcription elongation through the FXN gene and induce transcriptional silencing that is restricted to the FXN locus. Hum Mol Genet. 2015 Dec 15; 24(24):6932-43.
Score: 0.031
-
Delatycki MB, Tai G, Corben L, Yiu EM, Evans-Galea MV, Stephenson SE, Gurrin L, Allen KJ, Lynch D, Lockhart PJ. HFE p.C282Y heterozygosity is associated with earlier disease onset in Friedreich ataxia. Mov Disord. 2014 Jun; 29(7):940-3.
Score: 0.028
-
Mahishi LH, Hart RP, Lynch DR, Ratan RR. miR-886-3p levels are elevated in Friedreich ataxia. J Neurosci. 2012 Jul 04; 32(27):9369-73.
Score: 0.025
-
Brigatti KW, Deutsch EC, Lynch DR, Farmer JM. Novel diagnostic paradigms for Friedreich ataxia. J Child Neurol. 2012 Sep; 27(9):1146-51.
Score: 0.025
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|